Skip to main content
. 2015 Dec 1;26(4):228–242. doi: 10.1089/humc.2015.132

Figure 3.

Figure 3.

Distribution of AAV9-mediated persistent rNAGLU expression in the CNS and somatic tissues in C57BL/6 mice. WT C57BL/6 mice (8 weeks old) were treated with an IV injection of rAAV9-CMV-hNAGLU vector. Tissues were assayed by immunofluorescence (IF) for hNAGLU at 24 weeks pi. Red fluorescence: rNAGLU-positive cells and signals; blue fluorescence: DAPI-positive nuclei. NT, nontreated saline controls; AAV9-L, vector-treated at 1 × 1014 vg/kg; AAV9-H, vector-treated at 2 × 1014 vg/kg. (a) CNS tissues: CTX, cerebral cortex; TH, thalamus; BS, brain stem; CB, cerebellum; SC, spinal cord; yellow arrows, rNAGLU-positive neurons; green arrows, Purkinje cells; blue arrows, rNAGLU-positive blood vessels. (b) Somatic tissues: Liv, liver; Hrt, heart; yellow arrows, cardiomyocytes; blue arrows, blood vessels; lung, yellow arrows, rNAGLU-positive cells; Int, small intestine; ME, muscularis externa; white arrows, neurons myenteric plexus; pink arrows, neurons of submucosal plexus; panc, pancreas; IL, islets of Langerhans; AC, acinus. Scale bar: 50 μm.